Thus, the use of bioactive substances such as CTP, which activates Nrf2 to reduce the cellular level of ROS and inhibit the adipogenic differentiation of hASCs, could be a new strategy for overcoming obesity. This evidence concerns the gene NFE2L2 and obesity due to melanocortin 4 receptor deficiency.